实体器官移植患者侵袭性曲霉病住院期间三唑类与钙调神经磷酸酶或mTOR抑制剂的联用情况
该研究基于美国索赔数据库,纳入2015年10月至2022年11月因侵袭性曲霉病住院且接受系统抗真菌治疗≥3天的成人实体器官移植受者,描述三唑类与钙调神经磷酸酶抑制剂(CNI)或mTOR抑制剂的联用情况。共识别173例患者,三唑类使用率98.3%,其中81.8%与CNI或mTOR抑制剂联用,伏立康唑使用频率约为艾沙康唑的两倍。
要点
- 实体器官移植患者因侵袭性曲霉病住院时,三唑类与CNI或mTOR抑制剂联用率达81.8%。
- 伏立康唑使用率71.1%,艾沙康唑41.0%,前者约为后者两倍。
- 他克莫司是最主要使用的免疫抑制剂,占89.9%。
核心结论
- 尽管艾沙康唑药代动力学更可预测且严重药物相互作用倾向低于伏立康唑,伏立康唑使用频率仍约为艾沙康唑的两倍。
- 三唑类与CNI或mTOR抑制剂联用常见,可能导致严重药物相互作用,需剂量调整和治疗药物监测以减少严重不良事件。
研究设计与样本
- 基于美国索赔数据库的回顾性队列描述性研究。
- 纳入2015年10月至2022年11月因侵袭性曲霉病住院、接受系统抗真菌治疗≥3天且有实体器官移植史的成人患者,共173例。
主要发现
- 肾移植和肺移植最常见,两者均>42%。
- 三唑类用于170例(98.3%),平均用药时长116±184天(出院后)。
- 伏立康唑使用率71.1%,艾沙康唑41.0%,三唑类与CNI或mTOR抑制剂联用139例(81.8%)。
- 他克莫司为主要免疫抑制剂,使用率89.9%。
临床怎么用
- 对因侵袭性曲霉病住院的实体器官移植患者,应关注三唑类与CNI或mTOR抑制剂的药物相互作用。
- 联用时需进行剂量调整和治疗药物监测,以降低严重不良事件风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: All triazoles decrease the metabolism of calcineurin inhibitors (CNIs) and mammalian target of rapamycin (mTOR) inhibitors through CYP3A4 and P-glycoprotein inhibition leading to increased exposure and the potential for serious adverse events (SAEs). OBJECTIVES: We sought to describe triazoles and CNI and mTOR inhibitor use in solid organ transplantation (SOT) recipients hospitalized for invasive aspergillosis (IA). PATIENTS AND METHODS: We included adults with ≥1 claim for an IA admission in a US claims database from October 2015 to November 2022 who received systemic antifungal therapy for ≥3 days during the stay. This cohort was limited to patients with a history of SOT (defined as ≥1 diagnosis code for post-transplant status and/or complication) between January 2010 and IA admission. Triazoles and CNI or mTOR inhibitor co-administration in newly admitted IA patients were described. RESULTS: We identified 173 admitted IA patients with SOT. Kidney and lung transplant were most prevalent (>42% for both). Triazoles were used in 170 (98.3%) of patients (mean duration, 116 ± 184 post-admission days). Voriconazole (71.1%) and isavuconazole (41.0%) were most prescribed, and triazoles were co-administered with a CNI or mTOR inhibitor in 139 (81.8%) of patients. Tacrolimus was the predominantly used (89.9%) immunosuppressant. CONCLUSIONS: Voriconazole was used nearly twice as frequently as isavuconazole, despite isavuconazole having more predictable pharmacokinetics and a lower propensity for severe drug-drug interactions versus voriconazole. The still-frequent use of isavuconazole may reflect its lower inhibition of CNIs and mTOR inhibitors. Resulting drug-drug interactions may be serious and dose adjustment and therapeutic drug monitoring are needed to reduce SAEs.
引用
- Alexander B, Johnson MD, Lovelace B, et al. Co-administration of triazoles with calcineurin or mammalian target of rapamycin inhibitors in solid organ transplant patients hospitalized with invasive aspergillosis. J Antimicrob Chemother. 2026. PMID: 41414921. doi:10.1093/jac/dkaf461
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。